Financial Data and Key Metrics Changes - Total revenue for Q4 was approximately $128 million, down 5% year over year, driven by lower product revenue in China and EIMEA [10][21] - For the full fiscal year, total revenue reached a record $459 million, up 3% from last year, with international business growing 4% year over year [22] - Adjusted EBITDA for Q4 was $9.4 million, and for the full year, EBITDA was $28.3 million, up 44% year over year [26] Business Line Data and Key Metrics Changes - Product revenue in Q4 was $71 million, down 11% year over year, while service revenue was $57 million, up 4% year over year [22][23] - Full year service revenue was $221 million, up 4% from last year, with contract revenue now making up about 90% of total service revenue [23][16] - Service gross margins improved by nine points driven by lower parts consumption and successful pricing initiatives [25] Market Data and Key Metrics Changes - Revenue in China declined 14% year over year, while EIMEA saw a 34% decline [10] - APAC region revenue was up 22%, and The Americas saw a 24% increase, indicating strong performance outside the challenged regions [11] - For the full year, China product revenue grew 20% year over year, while EIMEA was down 32% [15] Company Strategy and Development Direction - The company aims to penetrate emerging markets and improve operational models with a focus on adjusted EBITDA and profitability [36] - A significant focus is on driving further adjusted EBITDA margin expansion through cost productivity and pricing actions [35] - The company is working on establishing a foreign trade zone to mitigate tariff impacts and enhance operational efficiency [32][29] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the U.S. market, expecting gradual improvement in fiscal year 2026 [19][50] - The geopolitical environment has created challenges, but the company has successfully navigated these through strategic actions [5][10] - Guidance for fiscal year 2026 includes a revenue range of $471 million to $485 million and an adjusted EBITDA range of $31 million to $35 million [39] Other Important Information - The company completed a comprehensive debt refinancing, enhancing financial flexibility and supporting long-term growth initiatives [28][19] - The company incurred approximately $4 million in cash tariffs in Q4, with half mitigated through various initiatives [34][54] Q&A Session Summary Question: Update on China market conditions - Management indicated that conditions in China have improved but have not fully returned to normal, with strong customer demand still present [42][43] Question: U.S. market improvement assumptions - Management noted that Q4 performance in The Americas was strong, with a focus on converting backlog and accelerating installations [50] Question: Outlook for Helix in India and other emerging markets - Management confirmed solid performance for Helix in its first year and expects growth in India and surrounding regions [52][53] Question: Tariff impact run rate for the upcoming fiscal year - Management confirmed a $4 million cash impact from tariffs, with expectations for similar run rates in fiscal year 2026 [54][55]

Financial Data and Key Metrics Changes - Revenues for the six months ended June 30, 2025, were $700,000, a decrease of $300,000 or 31% compared to $1,000,000 for the same period in 2024, primarily due to decreased participant demand for the Bahamas registry trial and reduced demand for contract manufacturing services [25][26] - Clinical trial revenue for the same period was $600,000, a decrease of $200,000 or 31% compared to $800,000 in 2024 [26] - General and administrative expenses increased to approximately $5,500,000, up from $4,300,000, representing a 28% increase [27] - Research and development expenses rose to approximately $5,500,000, a 39% increase from $3,900,000 in 2024 [27] - Net loss increased to approximately $10,000,000 for the six months ended June 30, 2025, compared to a net loss of $7,500,000 for the same period in 2024 [27][28] Business Line Data and Key Metrics Changes - The company is focused on three primary operational goals for 2025: advancing the pivotal Phase 2b study for SLHS, SLHS BLA preparedness, and pursuing strategic collaboration for the Alzheimer's disease program [6][30] - The SLHS program is considered a key strategic priority with a high probability of success and a shorter path to potential regulatory approval [6][30] Market Data and Key Metrics Changes - The U.S. market opportunities for the company's three initial indications are approximately $5 billion for Alzheimer's disease, over $4 billion for aging-related frailty, and up to $1 billion for hypoplastic left heart syndrome (HLHS) [5][6] - The prevalence of pediatric dilated cardiomyopathy is estimated to be around 2,000 to 3,000 patients in the U.S., while HLHS affects about 1,000 newborns [37] Company Strategy and Development Direction - The company is expanding its pipeline to include pediatric dilated cardiomyopathy and has licensed additional stem cell technology from the University of Miami [21][30] - The strategy focuses on excellent science, lower required investments, speed to market, and addressing important unmet medical needs [21] - The company plans to initiate a pivotal Phase 2 clinical trial for pediatric dilated cardiomyopathy in 2026 [18][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential BLA submission for SLHS in late 2026, contingent on positive trial results [28][30] - The company is focused on prudent capital allocation strategies to advance development programs, which are considered highly cost-efficient [28][29] - Management highlighted the importance of FDA interactions and the collaborative approach taken by the agency [8][56] Other Important Information - The company completed a public offering in August, raising approximately $5 million in gross proceeds [28] - The FDA has approved the IND application for evaluating laramestrocel as a treatment for pediatric dilated cardiomyopathy, allowing the company to move directly to a pivotal Phase 2 trial [17][18] Q&A Session Summary Question: Are the target patient populations and addressable markets for HLHS and pediatric dilated cardiomyopathy similar? - The markets are similar but not identical; HLHS has a one-time use administration while pediatric dilated cardiomyopathy involves continuous use [35][36] Question: Will a favorable approval decision in HLHS impact the regulatory outlook for pediatric dilated cardiomyopathy? - A positive outcome from the HLHS trial would support the regulatory review process for pediatric dilated cardiomyopathy, but the FDA will still require study results specific to that indication [41][42] Question: What is the estimated budget for the pediatric dilated cardiomyopathy trial? - Preliminary budget estimates for the entire trial range from $15 million to $20 million, with annual costs around $3 million [43][44] Question: Will the company retain the pediatric designation and associated benefits if the PRB sunsets? - The company is cautiously optimistic about the renewal of the PRB and has mechanisms in place for rolling submissions [51][53] Question: What gave the FDA confidence to allow the company to move directly to pivotal Phase 2 for pediatric dilated cardiomyopathy? - The FDA was confident due to the design of clinically meaningful endpoints and the company's robust safety data set from previous studies [67][72]

Financial Data and Key Metrics Changes - Revenue reached $117.2 million, representing an organic growth of 12.3% at constant currency compared to the same period last year [7][29] - Adjusted EBITDA margin was 18.4%, showing a sequential improvement from the first quarter [7][32] - Adjusted profit margin stood at 10.4%, with adjusted profit recorded at $12.2 million [32][33] Business Line Data and Key Metrics Changes - Revenue from Latin America increased by 26% year over year, while North America grew by 7% [30] - Revenue from the top 10 clients grew by 12% compared to the same period last year [30] Market Data and Key Metrics Changes - The company reported a 90% adoption rate of CINT Flow among its teams, indicating a significant integration of AI into operations [39] - The pipeline for new business is 25% higher than in the same period last year, reflecting strong demand [46] Company Strategy and Development Direction - The company focuses on embedding deeply with large clients and delivering clear value through tech integrated business solutions [6][34] - CINT has joined AWS's GenAI Partner Innovation Alliance, enhancing its capabilities in generative AI [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue target of at least $124.4 million for 2025, representing a year-over-year growth of at least 10.5% at constant currency [34] - The company maintains its adjusted EBITDA margin guidance in the range of 18% to 20% for the full year [35] Other Important Information - The company ended the second quarter with over 7,600 CINE tiers, a growth of more than 22% year over year [27] - The voluntary attrition rate remains at a healthy 10.6%, reflecting a strong company culture [28] Q&A Session Summary Question: Adoption of CINT Flow among clients and internal stakeholders - Adoption of CINT Flow is reaching 90% among teams, indicating that 90% of revenue is influenced by AI and CINT Flow [39] Question: Differences in AI adoption across different verticals - Financial services are leading in AI investments due to high ROI, while retail is still modernizing legacy systems [40][41] Question: Guidance increase due to visibility or demand - The guidance increase is supported by consistent performance and a solid commercial pipeline, which is 25% higher than last year [46] Question: Revenue growth breakdown - 90% of growth comes from existing clients, while 10% is from new clients [50] Question: EBITDA margin drivers - EBITDA margin improved due to seasonal factors, hiring investments, and efficiency gains from AI [56][58] Question: Client behavior around GenAI and AgenTeq work - Clients are recognizing the complexity of AI capabilities and are seeking partnerships for internalization of expertise [90][92]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $2.7 million, representing a 26% sequential increase, driven by the sale of eight systems [5][25] - Gross profit for Q2 2025 was $1.3 million, with a gross margin of 49.3%, an increase of 800 basis points sequentially [27] - Net loss for Q2 2025 was $9.2 million, equating to a net loss of $0.12 per share, consistent with the previous quarter [28] - Cash burn excluding financing decreased by 19% sequentially to $8.1 million [28] Business Line Data and Key Metrics Changes - The company sold eight units in Q2 2025, including its first next-generation subsystem, with a strong average selling price [5][25] - The new subsystem has a manufacturer’s suggested retail price (MSRP) of $550,000, approximately a 15% premium to the prior version [15] - The company is focused on expanding its sales in U.S. hospitals, office settings, and international markets [10][14] Market Data and Key Metrics Changes - The total market opportunity for the company's technology exceeds $6 billion, with a proprietary position as a first mover [9] - The company has begun rolling out its Optive AI software to its installed base, enhancing image quality significantly [7][10] - The company is actively engaged in international markets, with software now available in Canada, Australia, and New Zealand, and plans to launch in Europe by the end of 2025 [22] Company Strategy and Development Direction - The company aims to launch one new product every six months, having received FDA clearance for two major technologies ahead of schedule [6][9] - The next-generation subsystem and Optive AI software are seen as key pillars for future growth, with a focus on driving adoption across multiple care settings [12][14] - The company is transitioning from pilot programs to full launches in office settings, targeting neurology practices specifically [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong revenue growth in the second half of 2025, driven by multiple product launches and increased traction in various markets [23][30] - The company anticipates a sequential revenue increase of 50% in Q3 compared to Q2, with expectations for continued margin expansion [30][31] - Management highlighted the importance of cash burn reduction and disciplined spending as key focuses moving forward [28][29] Other Important Information - The company completed its office pilot program and is now launching its next-generation subsystem in the office setting [6][19] - The PRIME study at Yale School of Medicine is evaluating the potential of AI-powered portable MRI technology in emergency departments [18][19] - The company has seen a positive market response to its new products, with significant interest from clinicians [14][40] Q&A Session Summary Question: Guidance for 2025 revenue - Management maintained the full-year 2025 revenue guidance, indicating a significant step up in the second half, with Q3 expected to show a 50% increase over Q2 [37][38] Question: Next-gen SWOOP launch expectations - Management discussed the incremental revenue contributions from new system placements and upgrades, emphasizing a focus on new system sales [41][42] Question: Funnel interest and system placements - Management confirmed a focus on managing separate funnels for hospital and office opportunities, with expectations for increased placements in the second half [56][59] Question: ASP increases and international business impact - Management noted that ASP increases were driven by a favorable sales mix and higher MSRP for new technology, with expectations for continued growth [68][70] Question: Use cases for patients with neuro implants - Management highlighted the safety profile of the low-field strength system, which is favorable for patients with magnetic implants [73][74]

Financial Data and Key Metrics Changes - Forian reported second quarter revenue of $7.5 million, representing a 56% year-over-year growth, with the Kyber acquisition contributing approximately $1.9 million or 39% to this growth [8][15] - Net income for the quarter was $224,000, and adjusted EBITDA was $591,000, compared to a loss of $2.5 million and positive $78,000 year-over-year respectively [8][15] - Operating income was approximately $50,000 compared to a loss of $3 million in the same quarter last year, primarily due to higher revenues and lower stock-based compensation [16] Business Line Data and Key Metrics Changes - The growth in revenue was highlighted by key new pharma projects and analytical renewals, alongside the full quarter of Kyber Data Science's financials [8][15] - The company expanded its data coverage by securing new supply contracts and accelerating integrations with diverse clinical data sources [9] Market Data and Key Metrics Changes - The healthcare and financial services markets are experiencing a mixed spending environment, with pharma companies remaining cautious due to geopolitical and macroeconomic factors [7] - The demand for analytic-ready real-world data continues to grow, as companies seek to measure effectiveness, safety, and value [7] Company Strategy and Development Direction - Forian aims to continue entering into more strategic long-term data contracts and invest in enhancing its product portfolio [9] - The company is optimistic about 2025, expecting full-year revenue of $28 million to $30 million, representing 39% to 49% growth year-over-year [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the second half of the year based on contracted backlog and renewals in the pipeline [6] - The company is actively looking for strategic acquisitions to strengthen its financial position and expand its reach with pharmaceutical clients [13][21] Other Important Information - The company ended the period with $35.6 million in cash and marketable securities and $6.8 million in convertible notes maturing in September 2025 [17] - Adjusted EBITDA margin is expected to be between negative $1 million and positive $1 million for the full year [13] Q&A Session Summary Question: What will drive the delta between the top and bottom line of the guidance? - Management indicated that renewals in the back half of the year will significantly impact hitting the guidance range [20] Question: Can you discuss the acquisition environment and seller valuations? - Management noted that valuations are coming down from previous highs, and there are opportunities in the smaller market that align with the company's size [21][22] Question: Where were the strengths in organic growth and its sustainability? - The company highlighted health economics and outcomes research as strong growth areas, along with the Kyber data science division in financial services [25][26] Question: What factors could lead to a positive or negative adjusted EBITDA? - Management stated that discretionary spending on strategic initiatives and revenue performance will impact adjusted EBITDA [27] Question: Are new AI technologies improving productivity and cost efficiency? - Management is investigating the use of AI to enhance efficiency but noted that regulatory concerns limit rapid adoption [30][31]

Financial Data and Key Metrics Changes - Revenue in Q2 2025 totaled $3 million, a 134% increase from $1.3 million in the prior year period [14] - Gross profit was $600,000, representing 21% of revenue, compared to $300,000 or 25% in the prior year [15] - Net loss for Q2 2025 was $1.4 million, a 38% improvement from a net loss of $2.2 million in the prior year [16] - For the first half of 2025, net sales totaled $5 million, a 124% increase from $2.2 million in the prior year [17] Business Line Data and Key Metrics Changes - The RV market drove significant sales growth, contributing to the overall revenue increase [15] - The E360 product line showed strong sales growth, with over 300 customers nationwide [6][7] - Home energy storage solutions (HESS) began shipments in January 2025, targeting a fast-growing market [7][11] Market Data and Key Metrics Changes - The RV market is recovering, driven by increased interest in outdoor activities [9] - The home energy storage market is expected to surpass $123 billion globally by 2029 [13] - The industrial applications market is identified as a future growth vertical, particularly for electric forklifts [10] Company Strategy and Development Direction - The company is focused on expanding its battery portfolio across five markets: RV, marine, light electric vehicles, home energy storage, and industrial applications [9][11] - Long-term strategies include onshoring manufacturing of key components to reduce tariff exposure [8][16] - The company aims to leverage its reputation in the lithium battery space to broaden distribution channels [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future, citing substantial purchase orders and interest from new customers [19] - The company is actively pursuing tariff exclusion requests and has implemented inventory strategies to mitigate potential impacts [8][23] - Management highlighted the importance of sales mix in maintaining margins amid tariff uncertainties [25] Other Important Information - The company has 11 patents pending, indicating a robust intellectual property portfolio [11] - Cash and cash equivalents totaled $700,000 as of June 30, 2025, up from $500,000 at the end of 2024 [18] Q&A Session Summary Question: Current tariff environment and lobbying efforts in Washington, DC, has anything developed? - Management is confident in their lobbying efforts and believes they have a case for an exclusion [23] Question: How much prebuilt inventory is left for subsequent quarters? - The company has over $5 million in inventory available for sale, primarily from preloaded inventory purchased in late 2024 [24] Question: Does the China tariff pause help or will you pass price increases to customers or sell at lower margins? - The sales mix will be crucial, with expectations that battery sales will help maintain strong margins in the upcoming quarter [25]

Financial Data and Key Metrics Changes - As of June 30, 2025, the company had a cash balance of approximately $3.8 million [20] - For the three months ended June 30, 2025, consolidated operating expenses were approximately $1.8 million, down roughly $800,000 or 32% from $2.6 million a year ago [20][21] - The operating loss decreased to $1.8 million compared to $2.6 million from the previous year, reflecting progress in aligning resources with strategic priorities [21] Business Line Data and Key Metrics Changes - The company advanced its lead oncology indication clinical program and delivered preclinical results supporting broader applications, including long COVID, while significantly reducing operating expenses [7] - The first cohort of the Australian oncology trial completed Hemopurifier treatments without any device deficiencies or immediate complications [10] - An independent data safety monitoring board recommended advancing to the second treatment cohort after reviewing safety data from the first cohort [11] Market Data and Key Metrics Changes - The Australian oncology trial is designed to include patients on either monotherapy or combination therapy, increasing the potential pool of patients for the study [12] - The global economic burden of long COVID is approximately $1 trillion per year, indicating a large unmet medical need [15] Company Strategy and Development Direction - The company decided not to proceed with the India study to focus resources on the Australian trial, which is seen as the fastest track toward regulatory approval [7][8] - The focus remains on moving the Hemopurifier towards regulatory approval and expanding its use across multiple diseases [7] Management Comments on Operating Environment and Future Outlook - Management acknowledged the need to continue raising funds for clinical research, ideally through strategic partnerships rather than financial investors [31] - The decision to halt the Indian trial was primarily strategic, aimed at avoiding potential delays in moving forward to the PMA phase [31][34] Other Important Information - The company presented preclinical data on long COVID at a symposium, indicating the potential for the Hemopurifier to remove extracellular vesicles associated with long COVID [15][16] - The company is actively recruiting additional sites in Australia to speed up patient enrollment for the clinical trial [42] Q&A Session Summary Question: Is the primary endpoint of the Australian study safety, and is the company on track to meet it? - Management confirmed that the first cohort has been treated without adverse events, indicating progress towards meeting the primary endpoint [25][26] Question: How does the preclinical data translate to actual patient treatment? - Management acknowledged that lab results may not directly reflect patient outcomes, emphasizing the importance of data from actual patients [27][28] Question: What are the implications of not moving forward with the Indian trial? - Management stated that the decision was strategic to avoid delays in regulatory approval, although cost savings were also a factor [30][31][34] Question: Will the company be able to speed up enrollment in the Australian trial? - Management confirmed efforts to speed up enrollment, including recruiting additional sites and using clinical trial liaisons and social media campaigns [41][42]

Codexis (CDXS) Q2 2025 Earnings Call August 13, 2025 04:30 PM ET Speaker0Welcome to Codexis Second Quarter twenty twenty five Earnings Conference Call. Please note this event is being recorded. And now I'll turn the call over to Georgia Abeers, Chief Financial Officer. Please go ahead.Speaker1Thank you, operator. With me today are Doctor. Stephen Dilly, Codexis' Chairman and Chief Executive Officer and Kevin Norick, Chief Operating Officer. During this call, we will be making a number of forward looking sta ...

Financial Data and Key Metrics Changes - The company recorded its highest quarterly revenue to date, achieving a 15% increase in sequential quarter revenue through sales of Quellimmune therapy, with revenue for Q2 2025 at $338,000 compared to approximately $293,000 in Q1 2025 and $0 in Q2 2024 [27] - Year-to-date revenue reached $631,000, attributed to existing customers expanding their usage of Quellimmune and the addition of new hospital customers [27] - The net loss for Q2 2025 declined to $2,000,000 compared to a loss of $3,200,000 in Q2 2024 [28] Business Line Data and Key Metrics Changes - Quellimmune net revenue for Q2 increased 15% sequentially, with a nearly 370% increase in revenue in the first six months of launch compared to the previous year [6][11] - The company added three new customers for Quellimmune since the beginning of Q2, indicating strong enthusiasm for the therapy [10] Market Data and Key Metrics Changes - The total U.S. market opportunity for the adult SCD therapy is estimated to be over $4 billion annually, with a potential patient population of approximately 200,000 facing organ failure [12] - The company has received FDA breakthrough device designation for five additional indications, indicating a significant market potential for adult indications [13] Company Strategy and Development Direction - The company aims to complete the neutralized AKI pivotal trial for adults and prepare to file a PMA following the trial's completion [30] - The broader strategy includes expanding the use of FCD therapy across a range of hyper-inflammatory conditions beyond AKI, targeting both pediatric and adult populations [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future prospects for SeaStar Medical, particularly regarding the adult AKI market and the potential for significant revenue generation [31] - The company is focused on enrolling the right type of patients in clinical trials to demonstrate therapeutic effects effectively [19] Other Important Information - The company raised $12.4 million in new equity capital through public offerings and registered direct offerings [26] - The gross profit margin for Q2 was approximately 92%, reflecting the transition to recognizing COGS as the company moves into commercial operations [28] Q&A Session Summary Question: What are the expectations for the adult AKI pivotal trial? - Management expects to reach full enrollment by the end of the year and plans to file a PMA in 2026 if the data supports it [22][32] Question: How is the company addressing the enrollment pace in clinical trials? - The company is actively adding new sites and expanding screening into additional ICUs to optimize enrollment rates [21][22]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $564,000, down from $901,000 in the same period last year, with a six-month revenue of $1,300,000 compared to $1,600,000 in the prior year [9] - Gross profit was $245,000 or 43% of revenue in Q2 2025, compared to $470,000 or 52% of revenue in the prior year quarter, with a six-month gross profit of $568,000 or 44% of revenue compared to $940,000 or 58% in the previous year's period [10] - Operating expenses totaled $3,100,000 in Q2 2025, down from $4,300,000 in the prior year period, reflecting a 29% reduction driven by lower expenses across various departments [11] - Net loss for Q2 was $2,800,000 or $0.36 per share, compared to a net loss of $3,800,000 or $8.16 per share in 2024, with a six-month net loss of $6,400,000 compared to $7,400,000 in the same year-ago period [12] Business Line Data and Key Metrics Changes - The Catamaran platform is advancing with real-world adoption in complex spine procedures, supported by FDA clearance for uses in thoracolumbar fixation [4] - The Catamaran SE, a second-generation low-profile implant, is on track for full commercial launch in the coming weeks, with positive feedback from alpha reviews [4] - The company is preparing for initial alpha surgeries using the newly developed Symmetry Plus system, expected to begin in Q4 2025 [5] Market Data and Key Metrics Changes - The strategic acquisition of SciVantage enhances the company's commercial organization and market access, providing new pathways through hospital approval processes and distribution networks [3] - The acquisition is expected to increase active case volume and revenue-generating technologies, contributing to the company's growth trajectory [2] Company Strategy and Development Direction - The company is focused on delivering solutions that promote true biologic fusion and structural stability for patients with sacropelvic disorders, with a commitment to driving value for patients, physicians, and shareholders [14] - The integration of SciVantage is expected to create a more diversified product offering, allowing the company to address various clinical needs in the sacropelvic region [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from the recent decline in revenue, anticipating a quick rebound as the integration with SciVantage progresses [28] - The company is optimistic about the upcoming launches of Catamaran SE and Symmetry Plus, which are expected to drive top-line growth [12][44] Other Important Information - The company ended the quarter with $7,800,000 in cash and no debt, providing flexibility to execute its strategic roadmap [12] - The company hosted 16 physician workshops in Q2 to support long-term adoption strategies and accelerate the learning curve for new users [7] Q&A Session Summary Question: How does the acquisition help achieve scale? - Management confirmed that the acquisition provides a pathway to scale and enhances access to hospital systems and contract groups, allowing for a more diversified product offering [17][20] Question: What is the timeline for filing audited financials for the acquisition? - The company indicated a 75-day post-close period to file the audited financials for SciVantage, expected by mid-October [24][27] Question: How should investors view Catamaran revenues in Q3 and Q4? - Management suggested that Q2 was disrupted by the acquisition process but expects a quick recovery in Catamaran revenues moving forward [28][30] Question: What is the reimbursement landscape for the new products? - The new products will participate in existing CPT codes for SI procedures, similar to the Catamaran system, with a focus on supporting technologies with data [40][41] Question: What is the expected impact of the Symmetry Plus launch? - The Symmetry Plus launch is anticipated to begin with alpha surgeries in October, with a full-scale launch expected early next year [44]